Effectiveness of sentinel lymph node surgery after chemotherapy in node-positive breast cancer

Extending adjuvant trastuzumab treatment time provided no additional benefit

Cognitive problems may be present before chemotherapy in women with breast cancer

BEATRICE study, adjuvant bevacizumab did not improve invasive disease-free survival in triple-negative breast cancer

New agents and mTOR inhibitors

HDAC inhibitors sensitise triple-negative breast cancer cells to PARP inhibition and cisplatin treatment

Diverse genetic alterations in triple-negative breast cancers after neoadjuvant chemotherapy

Young women with breast cancer more likely to respond to neoadjuvant chemotherapy

Chemo after complete surgical removal of local or regional breast cancer recurrence increases survival rates

Transcriptional regulation of endothelial cell differentiation

Highlights from the 4th EUTROC meeting

The AKT pathway and chemotherapy resistant ovarian cancer